Search Within

Michael Morris

Formats
  1. Meeting Abstract (275)
  2. Journal Article (268)
  3. Review (20)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (586)
  2. Genitourinary Oncology Service (586)
  3. Solid Tumor Oncology Division (586)
  4. Radiology, Department of (164)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (141)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (27)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (44)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (44)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (586)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Perspectives on telemedicine visits reported by patients with cancer
    Journal Article

    Doshi, S. D.; Khadem Charvadeh, Y.; Seier, K.; Bange, E. M.; Daly, B.; Lipitz-Snyderman, A.; Polubriaginof, F. C. G.; Buckley, M.; Kuperman, G.; Stetson, P. D.; more...
    JAMA Network Open (2024)

    Fulltext@MSK | Save
  • Targeted therapy in prostate cancer: Beyond PSMA [Interview]
    Miscellaneous

    Morris, M. J.
    Clinical Advances in Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)
    Journal Article

    Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Miller, B. C.; Hillman, D. W.; Heller, G.; Druley, T.; Armstrong, A. J.; Morris, M. J.; Milowsky, M. I.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Multivariable models of outcomes with [(177)Lu]Lu-PSMA-617: Analysis of the phase 3 VISION trial
    Journal Article

    Herrmann, K.; Gafita, A.; de Bono, J. S.; Sartor, O.; Chi, K. N.; Krause, B. J.; Rahbar, K.; Tagawa, S. T.; Czernin, J.; El-Haddad, G.; more...
    eClinicalMedicine (2024)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Apolo, A. B.; Sridhar, S. S.; Chen, R. C.; Wen, Y.; Yen, A. E.; Grivas, P.; Tan, A. L.; Baghaie, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer
    Meeting Abstract

    Shen, F.; Kelly, W. K.; Pandit-Taskar, N.; McDevitt, T.; Smith, R.; Menard, K.; Packman, K.; Chaudhary, R.; Rupnow, B.; Yu, M. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results
    Meeting Abstract

    Herrmann, K.; Gafita, A.; De Bono, J. S.; Sartor, A. O.; Chi, K. N.; Krause, B. J.; Rahbar, K.; Tagawa, S. T.; Czernin, J.; El-Haddad, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial
    Journal Article

    Morris, M. J.; de Bono, J.; Nagarajah, J.; Sartor, O.; Wei, X. X.; Nordquist, L. T.; Koshkin, V. S.; Chi, K. N.; Krause, B. J.; Herrmann, K.; more...
    Cancer (2024)

    Fulltext@MSK | Save
  • (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial
    Journal Article

    Morris, M. J.; Castellano, D.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N.; Crosby, M.; Piulats, J. M.; FleĢchon, A.; Wei, X. X.; more...
    Lancet (2024)

    Fulltext@MSK | Save